Title:
VAP POLYPEPTIDE AND USE THEREOF IN PREPARATION OF DRUG FOR TARGETED DIAGNOSIS AND TREATMENT OF TUMOUR
Document Type and Number:
WIPO Patent Application WO/2018/103660
Kind Code:
A1
Abstract:
Provided in the present invention are highly stable D-configuration polypeptides DVAP and SVAP having a high binding activity to the GRP78 protein, and also provided are an L-configuration polypeptide LVAP and a DVAP-or SVAP-modified model drug and a macromolecule carrier material, and the use thereof in the construction of a tumour image and a drug-delivery system for targeted treatment.
More Like This:
Inventors:
LU WEIYUE (CN)
RAN DANNI (CN)
MAO JIANI (CN)
XIE CAO (CN)
RAN DANNI (CN)
MAO JIANI (CN)
XIE CAO (CN)
Application Number:
PCT/CN2017/114796
Publication Date:
June 14, 2018
Filing Date:
December 06, 2017
Export Citation:
Assignee:
UNIV FUDAN (CN)
International Classes:
C07K7/06; A61K38/08; A61K49/00; A61P35/00
Foreign References:
| US20080003200A1 | 2008-01-03 |
Other References:
YAO, V.J. ET AL.: "Ligand-Targeted Theranostic Nanomedicines against Cancer", JOURNAL OF CONTROLLED RELEASE, vol. 240, 28 October 2016 (2016-10-28), pages 267 - 286, XP029759365, Retrieved from the Internet
See also references of EP 3553074A4
See also references of EP 3553074A4
Attorney, Agent or Firm:
INNOWISE INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF:
Previous Patent: HARQ FEEDBACK SCHEME FOR 5G NEW RADIO
Next Patent: METHOD, DEVICE AND APPARATUS FOR TRANSMITTING VOICE DATA
Next Patent: METHOD, DEVICE AND APPARATUS FOR TRANSMITTING VOICE DATA